Use of R(+) -α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piper idinemethanol for the treatment of sleep disorders

• US 6,613,779 B2
• Filed: 06/21/2001
• Issued: 09/02/2003
• Est. Priority Date: 08/28/1998
• Status: Expired due to Term

• Current Assignee: Aventisub II, Inc. (Sanofi )
• Original Assignee: Aventis Pharmaceuticals Incorporated (Sanofi )
• Inventors: Hitchcock, Janice M., Sorensen, Stephen, Mondadori, Cesare
• Primary Examiner(s): Cook, Rebecca
• Application Number:
  US09/886,424
• Publication Number:
  US 20010041719A1
• Time in Patent Office: 803 Days
• Field of Search: 514/317
• US Class Current: 514/317
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives

Abstract

A method of treating a patient for a Sleep Disorder comprising administering an effective amount of R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

Claims

1. A method of treating a patient for a sleep disorder by administering to the patient a therapeutically effective amount of R-(+)-α

-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the sleep disorder is insomnia.

3. The method of claim 1 wherein the sleep disorder is primary insomnia.

4. The method of claim 1 wherein the sleep disorder is insomnia associated with a mental disorder.

5. A monotherapeutic method of treating a patient for a sleep disorder and a condition selected from the group consisting of schizophrenia, fibromyalgia, obsessive compulsive disorder, coronary vasospasm, thrombotic illness, angina, anorexia nervosa, Raynaud'"'"'s phenomenon, extrapyramidal symptoms, anxiety, arrhythmia and bipolar depression, comprising administering to the patient in need of said method a therapeutically effective amount of R-(+)-α

-(2,3-dimethoxyphenyl)1-[2-(4-fluorophenyl)ethyl ]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the sleep disorder is insomnia.

7. The method of claim 5 wherein the sleep disorder is primary insomnia.

8. The method of claim 5 wherein the sleep disorder is insomnia associated with a mental disorder.

9. The method of claim 5 wherein the sleep disorder is substance-induced insomnia.

10. The method of claim 5 wherein the condition is schizophrenia.

11. The method of claim 5 wherein the condition is fibromyalgia.

12. The method of claim 5 wherein the condition is obsessive compulsive disorder.

13. The method of claim 5 wherein the condition is coronary vasospam.

14. The method of claim 5 wherein the condition is thrombotic illness.

15. The method of claim 5 wherein the condition is angina.

16. The method of claim 5 wherein the condition is anorexia nervosa.

17. The method of claim 5 wherein the condition is Raynaud'"'"'s phenomenon.

18. The method of claim 5 wherein the condition is extrapyramidal symptoms.

19. The method of claim 5 wherein the condition is anxiety.

20. The method of claim 5 wherein the condition is arrhythmia.

21. The method of claim 5 wherein the condition is bipolar depression.

22. The method of claim 5 wherein the sleep disorder is insomnia and the condition is schizophrenia.

23. The method of claim 5 wherein the sleep disorder is obstructive sleep apnea and the condition is schizophrenia.

24. The method of claim 5 wherein the sleep disorder is primary insomnia and the condition is schizophrenia.

25. The method of claim 5 wherein the sleep disorder is substance-induced insomnia and the condition is schizophrenia.